Subscribe to
this category
r

Regulatory

A total of 44 posts are filed under Regulatory
Patent-to-Launch time for Orphan Drugs 2.3 Years Longer than Other Drugs, Report Finds
  Rare Daily Staff It takes 15.1 years on average to advance an orphan drug from the first patent filing to product launch—18 percent… Continue Reading
Anarchy in the U.K.
Rare disease patients in the United Kingdom face unusual barriers to accessing medicines because of the multiple review and reimbursement… Continue Reading
U.S. Food and Drug Administration Orphan Drug Designations in April 2018
Continue Reading
FDA Commissioner Seeks 13 Percent Funding Increase for fiscal 2019
Rare Daily Staff U.S. Food and Drug Administration Commissioner Scott Gottlieb went before lawmakers earlier this week to make the case for… Continue Reading
Why Patient Groups Shouldn’t Dismiss Report on Pharma Influence
Earlier this month, Kaiser Health News launched “Pre$cription for Power,” a database that tracks Big Pharma contributions to patient… Continue Reading
U.S. Food and Drug Administration Orphan Drug Designations in March 2018
Continue Reading
MHRA Grants FCS Patients in UK Early Access to Akcea’s Volanesorsen
Rare Daily Staff The U.K.’s Medicines & Healthcare products Regulatory Agency said it would allow patients with the rare genetic lipid… Continue Reading
1 2 3 7
be-a-guest-blogger

Follow us on Twitter